Hematology in Clinical Practice最新文献_第2页

Plasmablastic lymphoma in an HIV-negative patient with complete remission after chemotherapy with DA-EPOCH DA-EPOCH化疗后完全缓解的hiv阴性患者的浆母细胞淋巴瘤

Hematology in Clinical Practice Pub Date : 2023-02-28 DOI: 10.5603/hcp.a2022.0016

Joseph Alburqueque-Melgarejo, Juan C. Roque-Quezada, Javier Dulanto Moscoso, Emanuel Salcedo Davila, Brady Beltrán Gárate

引用次数: 0

Therapeutic options in high-risk myelodysplastic syndrome 高危骨髓增生异常综合征的治疗选择

Hematology in Clinical Practice Pub Date : 2023-02-28 DOI: 10.5603/hcp.a2022.0017

Marcela Maksymowicz, Sara Moqbil, P. Machowiec, M. Podhorecka

引用次数: 1

Burkitt-like lymphoma with 11q aberration mimicking appendicitis in a young man — a diagnostic and therapeutic challenge 一名年轻男性伴有11q畸变的类似阑尾炎的伯基特样淋巴瘤——诊断和治疗的挑战

Hematology in Clinical Practice Pub Date : 2022-05-21 DOI: 10.5603/hcp.a2022.0008

R. Swoboda, Karolina Gajda, Roman Lamch, S. Giebel

引用次数: 0

Midostaurin in the treatment of a patient with acute myeloid leukaemia with FLT3-TKD mutation and NPM1 mutation midoin治疗FLT3-TKD突变和NPM1突变的急性髓性白血病1例

Hematology in Clinical Practice Pub Date : 2022-05-20 DOI: 10.5603/hcp.2022.0006

Aleksander Salomon-Perzyński, U. Walczak, Kinga Kos-Zakrzewska, E. Lech-Maranda, B. Budziszewska

引用次数: 0

Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features 美度舒林联合强化化疗后异基因造血干细胞移植治疗具有临床高危特征的NPM1和FLT3-TKD突变急性髓系白血病的疗效

Hematology in Clinical Practice Pub Date : 2022-05-20 DOI: 10.5603/hcp.2022.0004

E. Patkowska, M. Prochorec-Sobieszek, E. Lech-Maranda, B. Nasiłowska-Adamska

引用次数: 0

Polyserositis (pericarditis and bilateral pleural effusion) after COVID-19 mRNA vaccine COVID-19 mRNA疫苗后多浆膜炎(心包炎和双侧胸腔积液)

Hematology in Clinical Practice Pub Date : 2022-05-20 DOI: 10.5603/hcp.a2022.0001

K. Korzeniowska, A. Cieślewicz, Anna Flotyńska, A. Jabłecka

{"title":"Polyserositis (pericarditis and bilateral pleural effusion) after COVID-19 mRNA vaccine","authors":"K. Korzeniowska, A. Cieślewicz, Anna Flotyńska, A. Jabłecka","doi":"10.5603/hcp.a2022.0001","DOIUrl":"https://doi.org/10.5603/hcp.a2022.0001","url":null,"abstract":"The coronavirus disease 2019 (COVID-19) pandemic has been responsible for more than 5.5 million deaths worldwide. Vaccination is the most effective method of preventing this type of disease. The efficacy and safety of COVID-19 vaccines authorized in the European Union have been assessed in clinical trials that recruited many participants. As the number of vaccinated people increases, infrequent adverse effects are expected. We would like to report a case of polyserositis (pericarditis, and bilateral pleural effusion) observed a few days after administering the Pfizer BioNTech COVID-19 mRNA vaccine (Comirnaty ® ) in a 65-year-old man with no cardiovascular, metabolic or autoimmune disorders in his history. The incidence of myocarditis and pericarditis after COVID-19 mRNA vaccines is very low (combined reports from the USA and EU suggest the incidence of 1.02 × 10 –5 and 7.61 × 10 –6 respectively). Therefore, it is vital to inform people vol-unteering for vaccination to be aware of such symptoms as chest pain, breathlessness, or irregular forceful heartbeat. Moreover, the presence of these symptoms should alert healthcare professionals to the potential risk of pericarditis associated with the administration of the COVID-19 vaccine.","PeriodicalId":284891,"journal":{"name":"Hematology in Clinical Practice","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126447858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Hematological manifestations of X-linked lymphoproliferative disease x连锁淋巴细胞增生性疾病的血液学表现

Hematology in Clinical Practice Pub Date : 2022-05-20 DOI: 10.5603/hcp.a2022.0002

N. Dułak, Jadwiga Juwa, Rafał Trzciński, Alan Majeranowski, N. Irga-Jaworska

引用次数: 0

IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia 慢性淋巴细胞白血病患者IGHV突变状态和一线治疗的选择

Hematology in Clinical Practice Pub Date : 2022-05-20 DOI: 10.5603/hcp.2022.0003

B. Puła, K. Jamroziak, T. Wróbel, K. Giannopoulos, I. Hus

引用次数: 0

Treatment of a patient with acute myeloid leukaemia with FLT3-ITD mutation FLT3-ITD突变急性髓性白血病1例的治疗

Hematology in Clinical Practice Pub Date : 2022-05-20 DOI: 10.5603/hcp.2022.0005

K. Jerzmanowska, A. Pluta

引用次数: 0

Adverse events of monoclonal antibodies use in therapy of hematological malignancies 单克隆抗体用于治疗血液系统恶性肿瘤的不良事件

Hematology in Clinical Practice Pub Date : 2022-02-18 DOI: 10.5603/hcp.2021.0014

Marcela Maksymowicz, M. Podhorecka

{"title":"Adverse events of monoclonal antibodies use in therapy of hematological malignancies","authors":"Marcela Maksymowicz, M. Podhorecka","doi":"10.5603/hcp.2021.0014","DOIUrl":"https://doi.org/10.5603/hcp.2021.0014","url":null,"abstract":"Monoclonal antibodies given as monotherapy or combination therapy have emerged as effective treatment options for hematologic malignancies. By prolonging survival, mAbs reduced mortality and improved the clinical prognosis for patients with these diseases. However, despite the effective anticancer activity of mAbs, they induce adverse events. The most common side effects are infusion related reactions (IRR), associated with cytokine release within the first few hours after administra tion. IRR are usually mild to moderate and manifest in rash, fever, nausea, vomiting, dizziness, headache, hypotension or tachycardia. Other, common toxicities are cytopenias, increasing the risk of infections and bleeding. Most preventive strategies involve the use of glucocorticosteroids, acetaminophen, antihistamines, screening for antibodies against microorganisms and prophylaxis for infections. Cytokine release syndrome, cardiac, pulmonary, neurologic adverse effects occur less frequently. In cases of grade 1–2 toxicity, symptomatic management is recommended, but in more severe symptoms temporary or permanent discontinuation of therapy and use of glucocorticosteroids are recommended. In an effort to limit the incidence and severity of adverse events clinicians should know how to early recognize, precisely assess and timely manage.","PeriodicalId":284891,"journal":{"name":"Hematology in Clinical Practice","volume":"369 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116324005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0